|
21 Companies |
|
32 Products |
|
32 Products |
|
37 Mechanisms of Action |
|
0 Trials |
|
64 News |
|
| 12» |
- | Trial termination: Vaccine Therapy in Treating Patients With Myelodysplastic Syndromes (clinicaltrials.gov) - Nov 16, 2018
P1, N=9, Terminated, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Active, not recruiting --> Terminated; Loss of funding
- paricalcitol / Generic mfg.
Trial completion: Paricalcitol in Treating Patients With Myelodysplastic Syndrome (clinicaltrials.gov) - Jan 29, 2018
P2, N=0, Completed, Sponsor: Cedars-Sinai Medical Center
Active, not recruiting --> Terminated; Loss of funding Active, not recruiting --> Completed
- | Vesanoid (tretinoin) / Roche
Trial completion, Combination therapy: Phenylbutyrate and Tretinoin in Treating Patients With Hematologic Cancer (clinicaltrials.gov) - Sep 28, 2017
P1, N=0, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Active, not recruiting --> Completed No longer recruiting --> Completed
- | Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin
Phase classification: Azacitidine, Darbepoetin Alfa, and Erythropoietin and Filgastrim (G-CSF) in Treating Patients With Myelodysplastic Syndromes (clinicaltrials.gov) - Jun 20, 2017
P2, N=3, Terminated, Sponsor: Wake Forest University Health Sciences
No longer recruiting --> Completed Phase classification: P=N/A --> P2
- | vatalanib (PTK787) / Novartis, Bayer
Trial completion: Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes (clinicaltrials.gov) - Jul 30, 2016
P2, N=155, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Phase classification: P=N/A --> P2 Active, not recruiting --> Completed
- | topotecan / Generic mfg.
Trial completion: Topotecan in Treating Patients With Myelodysplastic Syndrome (clinicaltrials.gov) - Jul 18, 2016
P2, N=100, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion, Trial initiation date, Trial primary completion date: Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - May 19, 2016
P=N/A, N=20, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Recruiting --> Completed | Initiation date: Oct 2009 --> May 2009 | Trial primary completion date: Jan 2100 --> May 2016
- fludarabine IV / Generic mfg., busulfan / Generic mfg.
Clinical: Donor Stem Cell Transplant After Busulfan, Fludarabine, Methylprednisolone, and Antithymocyte Globulin in Treating Patients With Bone Marrow Failure Syndrome (clinicaltrials.gov) - Dec 31, 2015
P2, N=15, Completed, Sponsor: Asan Medical Center
Recruiting --> Completed | Initiation date: Oct 2009 --> May 2009 | Trial primary completion date: Jan 2100 --> May 2016 Recruiting --> Completed | N=50 --> 15 | Trial primary completion date: Mar 2014 --> Dec 2013
- Targretin oral (bexarotene oral) / ReXceptor, Leukine (sargramostim) / Partner Therap
Trial primary completion date: Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia (clinicaltrials.gov) - Nov 10, 2015
P2, N=26, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Recruiting --> Completed | N=50 --> 15 | Trial primary completion date: Mar 2014 --> Dec 2013 Trial primary completion date: Jul 2015 --> Jul 2016
- Trial primary completion date: Vaccine Therapy in Treating Patients With Myelodysplastic Syndromes (clinicaltrials.gov) - Nov 10, 2015
P0, N=7, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Trial primary completion date: Jul 2015 --> Jul 2016 Trial primary completion date: Dec 2015 --> Dec 2016
- | Trial completion, Enrollment change, Trial primary completion date: Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes (clinicaltrials.gov) - Jan 20, 2015
P2, N=17, Completed, Sponsor: Eastern Cooperative Oncology Group
Trial primary completion date: Dec 2015 --> Dec 2016 Suspended --> Completed | N=33 --> 17 | Trial primary completion date: Nov 2012 --> Feb 2014
- Ryoncil (remestemcel-L) / Mallinckrodt, Mesoblast
Trial withdrawal: OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies (clinicaltrials.gov) - Dec 5, 2014
P2, N=0, Withdrawn, Sponsor: Mesoblast International S
Suspended --> Completed | N=33 --> 17 | Trial primary completion date: Nov 2012 --> Feb 2014 Active, not recruiting --> Withdrawn
- Zolinza (vorinostat) / Merck (MSD)
Trial completion, Trial primary completion date: Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies (clinicaltrials.gov) - Nov 13, 2014
P2, N=12, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Withdrawn Active, not recruiting --> Completed | Trial primary completion date: Jun 2014 --> Mar 2014
- | lenalidomide / Generic mfg.
Trial completion: Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes (clinicaltrials.gov) - Jun 9, 2014
P1, N=24, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Trial primary completion date: Jun 2014 --> Mar 2014 Active, not recruiting --> Completed
- Zolinza (vorinostat) / Merck (MSD)
Enrollment closed: Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies (clinicaltrials.gov) - May 18, 2014
P2, N=12, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- fludarabine IV / Generic mfg., busulfan / Generic mfg.
Enrollment change: Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers (clinicaltrials.gov) - Mar 19, 2014
P2, N=1, Completed, Sponsor: University of California, Davis
Recruiting --> Active, not recruiting N=20 --> 1
- Targretin oral (bexarotene oral) / ReXceptor, Leukine (sargramostim) / Partner Therap
Enrollment change: Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia (clinicaltrials.gov) - Mar 19, 2014
P2, N=26, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
N=20 --> 1 N=18 --> 26
- Enrollment change: Vaccine Therapy in Treating Patients With Myelodysplastic Syndromes (clinicaltrials.gov) - Mar 19, 2014
P0, N=7, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
N=18 --> 26 N=15 --> 7
- fludarabine IV / Generic mfg., busulfan / Generic mfg.
Trial completion: Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers (clinicaltrials.gov) - Mar 19, 2014
P2, N=1, Completed, Sponsor: University of California, Davis
N=15 --> 7 Active, not recruiting --> Completed
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion: Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases (clinicaltrials.gov) - Mar 3, 2014
P3, N=230, Completed, Sponsor: The Canadian Blood and Marrow Transplant Group
Active, not recruiting --> Completed Recruiting --> Completed
- | amifostine / Generic mfg.
Trial completion: Amifostine in Treating Young Patients With Newly Diagnosed De Novo Myelodysplastic Syndromes (clinicaltrials.gov) - Feb 22, 2014
P2, N=10, Completed, Sponsor: Children's Oncology Group
Recruiting --> Completed No longer recruiting --> Completed
- | mycophenolate mofetil / Generic mfg.
Trial completion, Metastases: Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation (clinicaltrials.gov) - Feb 22, 2014
P2, N=0, Completed, Sponsor: Fred Hutchinson Cancer Research Center
No longer recruiting --> Completed Active, not recruiting --> Completed
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, NN1213 / Novo Nordisk
Trial completion: Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders (clinicaltrials.gov) - Feb 22, 2014
P2, N=0, Completed, Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | fludarabine IV / Generic mfg., busulfan / Generic mfg.
Trial completion: Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - Feb 22, 2014
P2, N=0, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion, Metastases: Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Avastin (bevacizumab) / Roche
Trial completion: Bevacizumab in Treating Patients With Myelodysplastic Syndrome (clinicaltrials.gov) - Feb 19, 2014
P1/2, N=0, Completed, Sponsor: Stanford University
Active, not recruiting --> Completed Not yet recruiting --> Completed
- | thalidomide / Generic mfg.
Trial completion: Thalidomide in Treating Patients With Myelodysplastic Syndrome (clinicaltrials.gov) - Feb 19, 2014
P2, N=29, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Completed No longer recruiting --> Completed
- | Leukine (sargramostim) / Partner Therap
Trial completion: Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer (clinicaltrials.gov) - Feb 19, 2014
P1, N=35, Completed, Sponsor: National Cancer Institute (NCI)
No longer recruiting --> Completed Active, not recruiting --> Completed
- | Enbrel (etanercept) / Pfizer, Amgen
Trial completion: Biological Therapy in Treating Patients With Myelodysplastic Syndrome (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | azacitidine / Generic mfg., sodium phenylbutyrate / Generic mfg.
Trial completion, Combination therapy: Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - Feb 19, 2014
P1, N=0, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Active, not recruiting --> Completed No longer recruiting --> Completed
- | Leukine (sargramostim) / Partner Therap
Trial completion: Vaccine Therapy in Treating Patients With Myelodysplastic Syndrome (clinicaltrials.gov) - Feb 19, 2014
P1, N=1, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
No longer recruiting --> Completed Active, not recruiting --> Completed
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, NN1213 / Novo Nordisk
Trial completion: Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Nonmalignant Hematologic Disease (clinicaltrials.gov) - Feb 19, 2014
P2, N=390, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases (clinicaltrials.gov) - Feb 19, 2014
P2, N=90, Completed, Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | thioguanine / Generic mfg.
Trial completion: Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome (clinicaltrials.gov) - Feb 19, 2014
P3, N=254, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed No longer recruiting --> Completed
- | decitabine / Generic mfg.
Trial completion: Decitabine in Treating Patients With Myelodysplastic Syndrome (clinicaltrials.gov) - Feb 19, 2014
P2, N=75, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
No longer recruiting --> Completed Active, not recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Pilot Study Of Unrelated UCB Transplant for Non-Malignant Hematologic Conditions (clinicaltrials.gov) - Feb 19, 2014
P2, N=6, Completed, Sponsor: Case Comprehensive Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, NN1213 / Novo Nordisk
Trial completion: Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma (clinicaltrials.gov) - Feb 19, 2014
P2/3, N=19, Completed, Sponsor: Virginia Commonwealth University
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | thioguanine / Generic mfg.
Trial completion: Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - Feb 19, 2014
P3, N=880, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed No longer recruiting --> Completed
- Enrollment open: Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 13, 2014
P=N/A, N=20, Recruiting, Sponsor: Children's Oncology Group
No longer recruiting --> Completed Active, not recruiting --> Recruiting
- amifostine / Generic mfg.
Enrollment change: Amifostine in Treating Young Patients With Newly Diagnosed De Novo Myelodysplastic Syndromes (clinicaltrials.gov) - Feb 10, 2014
P2, N=10, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Recruiting N=20 --> 10
- bortezomib / Generic mfg.
Enrollment change: Bortezomib in Treating Patients With Myelodysplastic Syndromes (clinicaltrials.gov) - Dec 11, 2013
P2, N=8, Completed, Sponsor: University of Rochester
N=20 --> 10 N=30 --> 8
- bortezomib / Generic mfg.
Trial completion: Bortezomib in Treating Patients With Myelodysplastic Syndromes (clinicaltrials.gov) - Dec 11, 2013
P2, N=8, Completed, Sponsor: University of Rochester
N=30 --> 8 Recruiting --> Completed
- Zolinza (vorinostat) / Merck (MSD)
Enrollment open: Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies (clinicaltrials.gov) - Oct 13, 2013
P2, N=12, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Not yet recruiting --> Recruiting
- Zarnestra (tipifarnib) / Kura Oncology
Trial completion: Tipifarnib in Treating Patients With Myelodysplastic Syndromes (clinicaltrials.gov) - Jun 30, 2013
P1, N=65, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Suspended --> Completed
- ||||| thioguanine / Generic mfg.
Enrollment change: Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome (clinicaltrials.gov) - Jun 25, 2013
P3, N=254, Completed, Sponsor: Children's Oncology Group
Suspended --> Completed N=158 --> 254
- decitabine / Generic mfg.
Trial completion: Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome (clinicaltrials.gov) - Feb 24, 2013
P1/2, N=25, Completed, Sponsor: Case Comprehensive Cancer Center
N=158 --> 254 Active, not recruiting --> Completed
- Zolinza (vorinostat) / Merck (MSD)
New P2 trial: Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies (clinicaltrials.gov) - Feb 10, 2013
P2, N=12, Recruiting, Sponsor: National Cancer Institute (NCI)
- Trial completion: Chemotherapy Plus Biological Therapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer (clinicaltrials.gov) - Feb 6, 2013
P2, N=16, Completed, Sponsor: University of Chicago
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Zarnestra (tipifarnib) / Kura Oncology
Trial initiation date: Tipifarnib in Treating Patients With Myelodysplastic Syndromes (clinicaltrials.gov) - Jan 15, 2013
P1, N=65, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Initiation date: Sep 2000 --> Jun 2002
- Leukine (sargramostim) / Partner Therap
Enrollment change: Vaccine Therapy in Treating Patients With Myelodysplastic Syndrome (clinicaltrials.gov) - Jan 14, 2013
P1, N=1, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Initiation date: Sep 2000 --> Jun 2002 N=70 --> 1